The global Stomach Cancer Treatment Market, valued at USD 4.3 billion in 2022, is on track for substantial growth, with forecasts projecting a surge to USD 11.47 billion by 2030. This growth trajectory is set at a robust compound annual growth rate (CAGR) of 13% over the forecast period spanning from 2023 to 2030.
Stomach cancer, also known as gastric cancer, remains one of the leading causes of cancer-related mortality worldwide. However, advancements in treatment modalities, early detection techniques, and personalized medicine approaches are driving significant improvements in patient outcomes and survival rates.
Get Sample PDf@ https://www.snsinsider.com/sample-request/3362
Key Players
The major key players are Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd, Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis, Bristol Myers Squibb Company and others.
Key factors propelling the growth of the Stomach Cancer Treatment Market include:
-
Advancements in Treatment Approaches: Ongoing research and development efforts have led to the introduction of novel treatment approaches for stomach cancer, including targeted therapies, immunotherapy, and minimally invasive surgical techniques, enhancing treatment efficacy and patient outcomes.
-
Early Detection and Diagnosis Initiatives: Increasing awareness about the importance of early detection and diagnosis of stomach cancer, coupled with advancements in diagnostic imaging technologies and biomarker identification, are enabling timely intervention and improving survival rates.
-
Rising Incidence of Stomach Cancer: The global burden of stomach cancer remains significant, with a rising incidence observed in several regions. This increase in disease prevalence is driving the demand for effective treatment options and contributing to market growth.
-
Growing Adoption of Personalized Medicine: The shift towards personalized medicine approaches, which aim to tailor treatment strategies based on individual patient characteristics and tumor biology, is driving the development of targeted therapies and precision oncology solutions in the field of stomach cancer treatment.
KEY SEGMENTS
By Treatment Type
-
Immunotherapy
-
Targeted Therapy
-
Chemotherapy
-
Radiation Therapy and Surgery
By Disease Indication
-
Gastric Cancer/Gastroesophageal Junction Cancer
-
Gastrointestinal Stromal Tumors
-
Route of Administration
-
Oral
-
Injectable
By Drug Class
-
PD-1/PD-L1 Inhibitors
-
HER2 Antagonists
-
VEGFR2 Antagonists
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Specialty & Retail Pharmacies
-
Others
The forecast period of 2023-2030 is expected to witness continued advancements in treatment modalities, as well as increased emphasis on multidisciplinary approaches to stomach cancer management, encompassing surgery, chemotherapy, radiation therapy, and supportive care interventions.
Geographically, North America currently dominates the Stomach Cancer Treatment Market, attributed to the presence of leading healthcare infrastructure, high adoption rates of advanced therapies, and robust research and development activities. However, regions such as Asia Pacific, Europe, and Latin America are anticipated to witness significant growth opportunities during the forecast period, driven by improving healthcare infrastructure and rising investments in cancer care initiatives.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Akash Anand – Head of Business Development & Strategy
info@snsinsider.com
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
Website: https://www.snsinsider.com